Dana-farber-cancer Institute Inc.

Emory University

Celldex Therapeutics Limited

Intrexon Corporation

Famewave Ltd.

The University of North Carolina at Chapel Hill

Research Corporation Technologies, Inc.

Biogen Ma Inc.

Schlumberger Technology Corporation

Tel Aviv University

Oxford University Innovation Ltd

Boyce Thompson Institute for Plant Research

Proclara Biosciences, Inc.

Vasgene Therapeutics, Inc

C2n Diagnostics LLC

Timothy David Jones

Francis Joseph Carr

Francis J Carr

Yaron R Hadari

James Peter Gregson

Gordon James Freeman

Rafi Ahmed

Elizabeth M Mandel-Bausch

Laura Clare Alexandra Perry

Robert George Edward Holgate

Yair Sapir

Gal Markel

Tehila Ben-Moshe

Jacob Schachter

Ilana Mandel

Rona Ortenberg

Robert George E Holgate

Simon William Keen

Michael Naso

Paul H Weinreb

Shelia Marie Violette

Kurt R Gehlsen

David Clemmons

Richard Fisher

Rajaraman Krishnan

Laura A Maile

Michael Tal

Ming Proschitsky

Eva Asp

Ronald Ellis

Robert G E Holgate

Anja Sibylle Tessarz

Sarit Samira

Nurit Rachamim

Arron Hearn

Li Jiang

Nathan Scott Lawrence

Charles Joel Arntzen

Go Fujisawa

Hugh S Mason

Diljeet Singh Athwal

Parkash S Gill

Beka Solomon

Steven Antony Gahlings

Rolf Rustad

Benjamin Guy Davis

Koen Hellendoorn

Valery Krasnoperov

Alemseged Truneh

Sheng Chao

Daniel Clive Anthony

Tim West

Nicola Ruth Sibson

Dwayne D Kirk

Xiuren Zhang

Yan Yang

Polina Rabinovich-Toidman

Richard Weldon

Lida Kimmel

Brett Robinson

Sreekala Mandiyan

Sandra Jane Campbell

Robin Patrick Choudhury

William Do Hamilton

Shahar Dotan

Idan Rakover

Meital Sooliman

Rom E Eliaz

Robert GE Holgate

Richard A Fisher

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.

Anti-kit antibodies and uses thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.

Anti-MET antibodies and methods of use thereof

Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Humanized antibodies against CEACAM1

The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.

Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal

Polynucleotides encoding humanized antibodies against CEACAM1

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

A sensor for monitoring COin a fluid regardless of the phase properties of the fluid, i.e., regardless of whether the fluid contacting the window is a liquid water-based phase, a liquid oil-based phase, a mixture of liquid water and liquid oil-based phases, or a gas phase. The sensor includes an internal reflection window for contacting with the fluid. A mid-infrared light source directs a beam of mid-infrared radiation into the window and the beam is internal reflected at an interface between the window and the fluid. The reflected beam is passed through three narrow bandpass filters which preferentially transmit mid-infrared radiation over bands of wavelengths corresponding to absorbance peaks of water, oil and CO. The amount of COis determined from the intensities of the mid-infrared radiation passing through the three filters.

Mid-infrared carbon dioxide sensor

Methods of treating by administering anti-kit antibodies

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Methods of treating a kit-associated cancer by administering anti-kit antibodies

The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.

Antibodies against CD106 (VCAM-1)

Humanized antibodies and antibody fragments thereof that bind to &#x3b1;v&#x3b2;6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent &#x3b1;v&#x3b2;6-mediated diseases such as fibrosis and cancer.

Anti-alpha V beta 6 antibodies and uses thereof

Humanized antibodies and antibody fragments thereof that bind to &#x3b1;v&#x3b2;6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent &#x3b1;v&#x3b2;6-mediated diseases such as acute tissue injury, fibrosis, and cancer.

Growing community of inventors

Babraham, United Kingdom

Timothy David Jones